Literature DB >> 7530391

Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies.

M E Hagensee1, J J Carter, G C Wipf, D A Galloway.   

Abstract

To assess the utility of vaccinia virus recombinants in the development of an immune response against HPV capsid antigens, 5-week-old C57B16 female mice were administered either purified HPV 1 capsids produced by a vaccinia virus recombinant or the recombinant vaccinia virus itself. Animals were boosted at Week 4 with either agent. Mice developed a serum IgG antibody response in all the administration protocols that was directed mainly against native L1 epitopes. Mice injected initially with the vaccinia virus recombinant and boosted with purified capsids had a higher titer antibody response (P = 0.024) with more mice responding to a greater extent. All mice produced a serum IgM response that preceded the IgG response by approximately 2 weeks and lasted 1-3 weeks. The IgM response was directed against native L1 epitopes. Although no serum IgA was detected, IgA could be detected in vaginal secretions of mice that were immunized or boosted with the vaccinia virus vector. These results indicate that an extensive humoral immune response to HPV can be elicited using vaccinia virus recombinants.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7530391     DOI: 10.1016/s0042-6822(95)80032-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

2.  Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.

Authors:  D W Liu; Y P Tsao; J T Kung; Y A Ding; H K Sytwu; X Xiao; S L Chen
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

Authors:  D Nardelli-Haefliger; R B Roden; J Benyacoub; R Sahli; J P Kraehenbuhl; J T Schiller; P Lachat; A Potts; P De Grandi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

4.  Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions.

Authors:  C Balmelli; R Roden; A Potts; J Schiller; P De Grandi; D Nardelli-Haefliger
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

5.  Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions.

Authors:  T Sasagawa; M Inoue; M Lehtinen; W Zhang; S E Gschmeissner; M A Hajibagheri; J Finch; L Crawford
Journal:  Clin Diagn Lab Immunol       Date:  1996-07

6.  Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes.

Authors:  C Dupuy; D Buzoni-Gatel; A Touzé; D Bout; P Coursaget
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

7.  A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

Authors:  Nadja Thönes; Anna Herreiner; Lysann Schädlich; Konrad Piuko; Martin Müller
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.